Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and adult toys.
Popular Articles

Rhode Island Hospital First In Country To Enroll Patient In New National Study For Treating Recurrent Chest Wall Breast Cancer
Rhode Island Hospital is one of only four sites across the country to participate in a new clinical trial called the DIGNITY Study. The study will investigate the effectiveness of a chemotherapeutic agent, ThermoDox, used in conjunction with mild hyperthermia (a form of heat therapy) for treating recurrent chest wall breast cancer.
buy viagra
New Study Results Verify That PNH Cells Are Found In Majority Of Patients With Bone Marrow Failure Syndromes
Paroxysmal nocturnal hemoglobinuria (PNH) cells are present in the majority of patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), and other bone marrow failure syndromes (BMF), according to interim results from 5,285 patients enrolled in the EXPLORE trial. EXPLORE (EXamination of PNH, by Level Of CD59 on REd and white blood cells) is the first large multicenter study to determine the frequency of PNH cells in these patient populations using a central laboratory conducting a high sensitivity test for PNH cells. The findings from EXPLORE will be presented tomorrow at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). The EXPLORE trial was sponsored by Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN).
News of the day
Myeloid Proteins Reflect Disease Activity And Treatment Response In Familial Mediterranean Fever
Serum levels of the pro-inflammatory biomarkers myeloid-related protein (MRP) 8 and 14 are increased to a greater extent in patients with Familial Mediterranean Fever (FMF) during flare than in patients with Neonatal-Onset Multisystem Inflammatory Disease (NOMID) or patients with Muckle Wells Syndrome (MWS), according to the results of a new study presented today at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
Sexual Health

As The Market Potential Grows, Developers Press For Keys To Delivering Systemic Drugs Via Inhalation

At a time when the drug industry is striving for patient-friendly delivery methods for new and existing drugs, the growing availability of innovative inhaler device designs is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While well-established for treating upper respiratory diseases such as asthma and COPD, companies competing in the inhaled drug delivery sector - major players such as GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim as well as pure-play start-ups - continue to view delivery of systemic drugs via inhalation as a major opportunity. The primary reason for the attraction of systemic pulmonary drug delivery lies in converging and related trends in population demographics and disease incidence. As the median age of the global population continues to increase, conditions and diseases such as menopause, osteoporosis, diabetes, and heart disease, which require long-term therapy, are expected to become significantly more prevalent. This is driving a growing emphasis on drug self-administration for chronic conditions and greater interest in noninvasive drug delivery technology. "The historical landscape for inhaled delivery of systemic drugs is marked by disappointment," explains Paul Brooks, Greystone Associates Senior Analyst. "But advances in drug formulation and inhalation device design are moving this technology approach closer to commercialization." Several of these development-stage drug products have the potential to make a significant impact in the therapeutic markets they target, improving patient compliance and effectively changing the way important illnesses and conditions are treated. Developments in this sector are the subject of a comprehensive analysis by Greystone Associates, and are contained in a just-released report that analyzes existing and emerging systemic inhalation products, market participants, and key demand and technology factors influencing the commercial market and shaping growth in this sector. More information is available here. Greystone Associates


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009